Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Alpha-antitrypsin Deficiency Treatment market report explains the definition, types, applications, major countries, and major players of the Alpha-antitrypsin Deficiency Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals, Inc
Digna Biotech, SL
Polyphor Ltd
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc
Sangamo BioSciences, Inc
Adverum Biotechnologies, Inc
ProMetic Life Sciences Inc
Applied Genetic Technologies Corporation
Inhibrx
Grifols, SA
Carolus Therapeutics, Inc
Editas Medicine, Inc
rEVO Biologics, Inc
Intellia Therapeutics, Inc
Arrowhead Pharmaceuticals, Inc
International Stem Cell Corporation
Kamada Ltd
By Type:
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
By End-User:
Clinic
Hospital
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Alpha-antitrypsin Deficiency Treatment Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Alpha-antitrypsin Deficiency Treatment Outlook to 2028- Original Forecasts
-
2.2 Alpha-antitrypsin Deficiency Treatment Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Alpha-antitrypsin Deficiency Treatment Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Alpha-antitrypsin Deficiency Treatment Market- Recent Developments
-
6.1 Alpha-antitrypsin Deficiency Treatment Market News and Developments
-
6.2 Alpha-antitrypsin Deficiency Treatment Market Deals Landscape
7 Alpha-antitrypsin Deficiency Treatment Raw Materials and Cost Structure Analysis
-
7.1 Alpha-antitrypsin Deficiency Treatment Key Raw Materials
-
7.2 Alpha-antitrypsin Deficiency Treatment Price Trend of Key Raw Materials
-
7.3 Alpha-antitrypsin Deficiency Treatment Key Suppliers of Raw Materials
-
7.4 Alpha-antitrypsin Deficiency Treatment Market Concentration Rate of Raw Materials
-
7.5 Alpha-antitrypsin Deficiency Treatment Cost Structure Analysis
-
7.5.1 Alpha-antitrypsin Deficiency Treatment Raw Materials Analysis
-
7.5.2 Alpha-antitrypsin Deficiency Treatment Labor Cost Analysis
-
7.5.3 Alpha-antitrypsin Deficiency Treatment Manufacturing Expenses Analysis
8 Global Alpha-antitrypsin Deficiency Treatment Import and Export Analysis (Top 10 Countries)
-
8.1 Global Alpha-antitrypsin Deficiency Treatment Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Alpha-antitrypsin Deficiency Treatment Export by Region (Top 10 Countries) (2017-2028)
9 Global Alpha-antitrypsin Deficiency Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global CT-2009 Consumption and Growth Rate (2017-2022)
-
9.1.2 Global POL-6014 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global ARO-AAT Consumption and Growth Rate (2017-2022)
-
9.1.4 Global ALNAAT-02 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Alpha-antitrypsin Deficiency Treatment Market Analysis and Outlook till 2022
-
10.1 Global Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.2.2 Canada Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.2.3 Mexico Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.2 UK Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.3 Spain Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.4 Belgium Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.5 France Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.6 Italy Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.7 Denmark Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.8 Finland Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.9 Norway Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.10 Sweden Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.11 Poland Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.12 Russia Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.3.13 Turkey Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.2 Japan Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.3 India Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.4 South Korea Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.5 Pakistan Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.6 Bangladesh Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.7 Indonesia Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.8 Thailand Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.9 Singapore Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.10 Malaysia Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.11 Philippines Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.4.12 Vietnam Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.2 Colombia Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.3 Chile Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.4 Argentina Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.5 Venezuela Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.6 Peru Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.7 Puerto Rico Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.5.8 Ecuador Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.6.2 Kuwait Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.6.3 Oman Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.6.4 Qatar Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.6.5 Saudi Arabia Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.6.6 United Arab Emirates Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.7.2 South Africa Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.7.3 Egypt Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.7.4 Algeria Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
-
10.8.2 New Zealand Alpha-antitrypsin Deficiency Treatment Consumption (2017-2022)
11 Global Alpha-antitrypsin Deficiency Treatment Competitive Analysis
-
11.1 Ionis Pharmaceuticals, Inc
-
11.1.1 Ionis Pharmaceuticals, Inc Company Details
-
11.1.2 Ionis Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Ionis Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.1.4 Ionis Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Alnylam Pharmaceuticals, Inc
-
11.2.1 Alnylam Pharmaceuticals, Inc Company Details
-
11.2.2 Alnylam Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Alnylam Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.2.4 Alnylam Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Digna Biotech, SL
-
11.3.1 Digna Biotech, SL Company Details
-
11.3.2 Digna Biotech, SL Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Digna Biotech, SL Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.3.4 Digna Biotech, SL Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Polyphor Ltd
-
11.4.1 Polyphor Ltd Company Details
-
11.4.2 Polyphor Ltd Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Polyphor Ltd Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.4.4 Polyphor Ltd Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Cevec Pharmaceuticals GmbH
-
11.5.1 Cevec Pharmaceuticals GmbH Company Details
-
11.5.2 Cevec Pharmaceuticals GmbH Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Cevec Pharmaceuticals GmbH Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.5.4 Cevec Pharmaceuticals GmbH Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Dicerna Pharmaceuticals, Inc
-
11.6.1 Dicerna Pharmaceuticals, Inc Company Details
-
11.6.2 Dicerna Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Dicerna Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.6.4 Dicerna Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Sangamo BioSciences, Inc
-
11.7.1 Sangamo BioSciences, Inc Company Details
-
11.7.2 Sangamo BioSciences, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Sangamo BioSciences, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.7.4 Sangamo BioSciences, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Adverum Biotechnologies, Inc
-
11.8.1 Adverum Biotechnologies, Inc Company Details
-
11.8.2 Adverum Biotechnologies, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Adverum Biotechnologies, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.8.4 Adverum Biotechnologies, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 ProMetic Life Sciences Inc
-
11.9.1 ProMetic Life Sciences Inc Company Details
-
11.9.2 ProMetic Life Sciences Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 ProMetic Life Sciences Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.9.4 ProMetic Life Sciences Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Applied Genetic Technologies Corporation
-
11.10.1 Applied Genetic Technologies Corporation Company Details
-
11.10.2 Applied Genetic Technologies Corporation Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Applied Genetic Technologies Corporation Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.10.4 Applied Genetic Technologies Corporation Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Inhibrx
-
11.11.1 Inhibrx Company Details
-
11.11.2 Inhibrx Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Inhibrx Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.11.4 Inhibrx Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Grifols, SA
-
11.12.1 Grifols, SA Company Details
-
11.12.2 Grifols, SA Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Grifols, SA Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.12.4 Grifols, SA Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Carolus Therapeutics, Inc
-
11.13.1 Carolus Therapeutics, Inc Company Details
-
11.13.2 Carolus Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Carolus Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.13.4 Carolus Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Editas Medicine, Inc
-
11.14.1 Editas Medicine, Inc Company Details
-
11.14.2 Editas Medicine, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Editas Medicine, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.14.4 Editas Medicine, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 rEVO Biologics, Inc
-
11.15.1 rEVO Biologics, Inc Company Details
-
11.15.2 rEVO Biologics, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 rEVO Biologics, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.15.4 rEVO Biologics, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Intellia Therapeutics, Inc
-
11.16.1 Intellia Therapeutics, Inc Company Details
-
11.16.2 Intellia Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Intellia Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.16.4 Intellia Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Arrowhead Pharmaceuticals, Inc
-
11.17.1 Arrowhead Pharmaceuticals, Inc Company Details
-
11.17.2 Arrowhead Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Arrowhead Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.17.4 Arrowhead Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 International Stem Cell Corporation
-
11.18.1 International Stem Cell Corporation Company Details
-
11.18.2 International Stem Cell Corporation Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 International Stem Cell Corporation Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.18.4 International Stem Cell Corporation Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Kamada Ltd
-
11.19.1 Kamada Ltd Company Details
-
11.19.2 Kamada Ltd Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Kamada Ltd Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
11.19.4 Kamada Ltd Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
11.19.5 Recent Research and Development Strategies
12 Global Alpha-antitrypsin Deficiency Treatment Market Outlook by Types and Applications to 2028
-
12.1 Global Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global CT-2009 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global POL-6014 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global ARO-AAT Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global ALNAAT-02 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Alpha-antitrypsin Deficiency Treatment Market Analysis and Outlook to 2028
-
13.1 Global Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.2.2 Canada Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.2.3 Mexico Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.2 UK Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.3 Spain Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.4 Belgium Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.5 France Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.6 Italy Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.7 Denmark Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.8 Finland Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.9 Norway Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.10 Sweden Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.11 Poland Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.12 Russia Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.3.13 Turkey Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.2 Japan Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.3 India Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.4 South Korea Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.8 Thailand Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.9 Singapore Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.11 Philippines Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.2 Colombia Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.3 Chile Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.4 Argentina Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.6 Peru Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.6.3 Oman Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.6.4 Qatar Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.7.2 South Africa Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.7.3 Egypt Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.7.4 Algeria Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Alpha-antitrypsin Deficiency Treatment Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Alpha-antitrypsin Deficiency Treatment
-
Figure of Alpha-antitrypsin Deficiency Treatment Picture
-
Table Global Alpha-antitrypsin Deficiency Treatment Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Alpha-antitrypsin Deficiency Treatment Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global CT-2009 Consumption and Growth Rate (2017-2022)
-
Figure Global POL-6014 Consumption and Growth Rate (2017-2022)
-
Figure Global ARO-AAT Consumption and Growth Rate (2017-2022)
-
Figure Global ALNAAT-02 Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Table North America Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure United States Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Canada Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Mexico Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure Germany Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure UK Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Spain Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Belgium Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure France Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Italy Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Denmark Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Finland Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Norway Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Sweden Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Poland Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Russia Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Turkey Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table APAC Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure China Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Thailand Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Singapore Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Philippines Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table South America Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure Brazil Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Colombia Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Chile Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Argentina Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Peru Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table GCC Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure Bahrain Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Oman Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Qatar Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table Africa Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure Nigeria Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Africa Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Egypt Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure Algeria Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table Oceania Alpha-antitrypsin Deficiency Treatment Consumption by Country (2017-2022)
-
Figure Australia Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Alpha-antitrypsin Deficiency Treatment Consumption and Growth Rate (2017-2022)
-
Table Ionis Pharmaceuticals, Inc Company Details
-
Table Ionis Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ionis Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Ionis Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Alnylam Pharmaceuticals, Inc Company Details
-
Table Alnylam Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alnylam Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Alnylam Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Digna Biotech, SL Company Details
-
Table Digna Biotech, SL Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Digna Biotech, SL Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Digna Biotech, SL Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Polyphor Ltd Company Details
-
Table Polyphor Ltd Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Polyphor Ltd Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Polyphor Ltd Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Cevec Pharmaceuticals GmbH Company Details
-
Table Cevec Pharmaceuticals GmbH Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cevec Pharmaceuticals GmbH Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Cevec Pharmaceuticals GmbH Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Dicerna Pharmaceuticals, Inc Company Details
-
Table Dicerna Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dicerna Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Dicerna Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Sangamo BioSciences, Inc Company Details
-
Table Sangamo BioSciences, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sangamo BioSciences, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Sangamo BioSciences, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Adverum Biotechnologies, Inc Company Details
-
Table Adverum Biotechnologies, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Adverum Biotechnologies, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Adverum Biotechnologies, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table ProMetic Life Sciences Inc Company Details
-
Table ProMetic Life Sciences Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table ProMetic Life Sciences Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table ProMetic Life Sciences Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Applied Genetic Technologies Corporation Company Details
-
Table Applied Genetic Technologies Corporation Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Applied Genetic Technologies Corporation Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Applied Genetic Technologies Corporation Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Inhibrx Company Details
-
Table Inhibrx Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Inhibrx Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Inhibrx Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Grifols, SA Company Details
-
Table Grifols, SA Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Grifols, SA Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Grifols, SA Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Carolus Therapeutics, Inc Company Details
-
Table Carolus Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Carolus Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Carolus Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Editas Medicine, Inc Company Details
-
Table Editas Medicine, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Editas Medicine, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Editas Medicine, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table rEVO Biologics, Inc Company Details
-
Table rEVO Biologics, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table rEVO Biologics, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table rEVO Biologics, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Intellia Therapeutics, Inc Company Details
-
Table Intellia Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intellia Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Intellia Therapeutics, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Arrowhead Pharmaceuticals, Inc Company Details
-
Table Arrowhead Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Arrowhead Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Arrowhead Pharmaceuticals, Inc Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table International Stem Cell Corporation Company Details
-
Table International Stem Cell Corporation Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table International Stem Cell Corporation Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table International Stem Cell Corporation Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Table Kamada Ltd Company Details
-
Table Kamada Ltd Alpha-antitrypsin Deficiency Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kamada Ltd Alpha-antitrypsin Deficiency Treatment Main Business and Markets Served
-
Table Kamada Ltd Alpha-antitrypsin Deficiency Treatment Product Portfolio
-
Figure Global CT-2009 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global POL-6014 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global ARO-AAT Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global ALNAAT-02 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Table North America Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure Germany Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure China Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure Brazil Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Alpha-antitrypsin Deficiency Treatment Consumption Forecast by Country (2022-2028)
-
Figure Australia Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Alpha-antitrypsin Deficiency Treatment Consumption Forecast and Growth Rate (2022-2028)
-
